The Oncology Institute Ansoff Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Unlock the Full Amsoff Matrix for Deeper Strategic Insight
This The Oncology Institute Amsoff Matrix Analysis gives a clear, company-specific view of growth options across market penetration, market development, product development, and diversification. What you see here is a real preview of the actual analysis, not just marketing copy, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Market Penetration
Deepen density in 100+ care sites
The Oncology Institute can lift share by sending more visits and infusions through its 100+ care sites across 5 states, rather than chasing distant growth. A denser footprint cuts friction for patients, improves referral capture, and can raise provider output without adding much fixed cost. In community oncology, even small gains in repeat visits and infusion use can boost revenue per episode, which matters when 2025 growth is tied to site-level efficiency.
Convert more referrals inside local markets
The Oncology Institute can win local market share by becoming the first stop for referrals from primary care doctors, hospitals, and specialists. In 2025, the American Cancer Society estimates about 2.0 million new U.S. cancer cases, so every faster handoff matters. When consult-to-treatment time is short and care is coordinated, more referred patients stay inside The Oncology Institute platform instead of drifting to hospital-employed or private-practice rivals.
Capture more ancillary revenue per episode
The Oncology Institute can lift penetration by keeping more medical oncology, radiation oncology, hematology, surgical oncology, and supportive care inside its own network. When patients get 2 or more treatment steps in-house, The Oncology Institute captures more ancillary revenue per episode and avoids leakage to outside providers. It also makes care simpler, which can improve follow-through and repeat use.
This matters because oncology care is already high-touch and multi-visit, so even one outsourced step can reduce margin and control. The tighter the in-house pathway, the more value The Oncology Institute can keep from each case.
Use value-based contracts to hold market share
The Oncology Institute fits market penetration best with value-based contracts that reward lower total cost, better site-of-care shifts, and tight care coordination. Payers now want predictable oncology spend, and ASCO says cancer care cost the U.S. more than $200 billion a year, so savings from fewer hospital infusions matter. In 2026, reimbursement discipline is as important as patient volume for holding share.
Raise retention through navigation and follow-up
The Oncology Institute can raise retention by tightening scheduling, navigation, and multidisciplinary follow-up, so patients move smoothly from diagnosis to active therapy to survivorship. Oncology episodes often last 6 to 18 months, which gives The Oncology Institute many touchpoints to keep one patient across several visits and service lines. Better follow-up also reduces drop-off between scans, infusions, and support care, which is where revenue leakage usually starts.
The Oncology Institute's 100+ Sites Are Built to Capture More Cancer Care
The Oncology Institute can grow share by pushing more visits and infusions through its 100+ sites across 5 states. With about 2.0 million U.S. cancer cases in 2025, faster referrals and tighter in-house care keep more patients inside The Oncology Institute network. That matters in a market where cancer care costs top $200 billion a year.
| 2025 signal | Why it helps |
|---|---|
| 100+ sites | Local share gain |
| 2.0M cases | More referrals |
| $200B+ cost | Value-based demand |
What is included in the product
Detailed Word Document
Editable Excel File
Market Development
Open de novo clinics in adjacent metros
The Oncology Institute can open de novo clinics in nearby metros with similar patient mixes, using the same care playbook for consults, infusion, and follow-up. The U.S. had about 2.0 million new cancer cases in 2025, so high-demand corridors can support enough visit volume to make each site work. This path scales faster and with less execution risk than redesigning the model from scratch.
Enter new states through partnerships
The Oncology Institute can enter new states with partnerships, joint ventures, and physician alignment, cutting the upfront cost of new sites and speeding referral trust. Partner-led entry is usually less capital heavy than a greenfield launch, which matters for a community oncology model built on local clinician ties. It also lets The Oncology Institute extend reach faster without waiting for a full owned network to ramp.
Use tele-oncology to widen reach
The Oncology Institute can use tele-oncology to enter smaller markets fast, pairing remote consults, follow-ups, and second opinions with hub-and-spoke care. One physician team can support several sites, so The Oncology Institute can avoid opening a full clinic on day 1 and still build local volume. That fits 2025 care patterns: more cancer care is moving to virtual touchpoints, while lower-density areas still need in-person infusion and procedures.
Target Medicare-dense growth markets
The Oncology Institute should target Medicare-dense markets with older populations, high cancer burden, and few specialist groups. In 2025, Medicare covers about 68 million people, and roughly 60% of new cancers occur in adults 65 and older, so these areas can support steady use across oncology, infusion, imaging, and supportive care.
Screening by payer mix, local competitors, and expected infusion volume lowers bad expansion bets. The Oncology Institute should favor geographies where one patient can drive 3 or more service lines, not just one visit stream.
Expand employer and health-system channels
The Oncology Institute can widen access by contracting with employers, health systems, and payer networks, which can steer covered lives into its care instead of waiting on walk-in referrals. Employer-sponsored insurance still covers about 165 million people in the U.S., so even small network wins can open large, repeatable patient pools. In 2026, this is one of the cleanest market-development moves because it uses the same clinical model to reach more lives.
The Oncology Institute's Growth Playbook: Expand Fast, Keep Care Model Intact
The Oncology Institute's market development path is to take its 2025 oncology model into new metros, states, and payer channels without changing core care delivery. With about 2.0 million U.S. cancer cases in 2025 and about 68 million Medicare enrollees, Medicare-heavy markets can support repeat visits, infusion, and follow-up. Partnerships and tele-oncology can speed entry and cut buildout risk.
| 2025 signal | Why it matters |
|---|---|
| 2.0M new U.S. cancer cases | Supports new-market demand |
| 68M Medicare lives | Targets older, high-use patients |
| 60% cancers age 65+ | Favors community oncology density |
What You See Is What You Get
The Oncology Institute Reference Sources
This is the actual The Oncology Institute Amsoff Matrix analysis document you'll receive upon purchase – no surprises, just professional quality. The preview below is taken directly from the full report, so you're seeing the same content included in the final download. Purchase unlocks the complete, in-depth version immediately.
Product Development
Broaden radiation oncology capacity
The Oncology Institute can broaden radiation oncology capacity to deepen its existing markets and keep more patients in-network. In oncology, where surgery, medical oncology, and radiation often need to work together, a fuller service stack can reduce leakage to outside providers and raise share of wallet. It also improves convenience for patients and can support tighter care coordination across the 2025 care cycle.
Scale clinical trials inside current clinics
The Oncology Institute can scale clinical trials inside its current clinics, turning the same patient base into a higher-value product without new sites. Trials add a differentiated care option for patients, create research-linked revenue, and can improve clinic economics. They also help physician recruiting, because oncologists often prefer groups with access to novel therapies and active protocols.
Build digital symptom monitoring tools
The Oncology Institute can add remote symptom tracking, nurse outreach, and digital follow-up to improve care between visits without opening new geography. In oncology, patients often stay in active care for 6 to 18 months and may have dozens of touchpoints, so even small gains in early symptom capture can reduce avoidable escalations. Digital symptom tools also help route higher-risk patients faster, which can lower ED use and protect clinic time. This is a low-capex product move that fits the existing care model.
Expand supportive care and navigation
The Oncology Institute can wrap active treatment with supportive care, navigation, and survivorship services to make the patient path smoother and more complete. Oncology patients often manage several needs at once, so this model can improve continuity, cut missed handoffs, and support complex care plans. It also gives The Oncology Institute a tighter, higher-touch service mix that can deepen loyalty without changing the core treatment line.
Grow hematology and infusion services
In 2025, the American Cancer Society projects 2.04 million new U.S. cancer cases, so The Oncology Institute can deepen its existing markets by adding more hematology and infusion therapies inside the same clinic footprint. That is classic product development: it raises touchpoints per patient, lifts visit density, and spreads fixed site costs over more billable services. More therapy types also keep patients inside The Oncology Institute network longer, which can support better site economics and retention.
TOI Expands Services to Deepen Patient Retention
The Oncology Institute's product development move is to add more services inside its existing clinics in 2025. Expanding hematology, infusion, trials, and digital symptom follow-up can lift visit density and keep patients in-network.
| 2025 data | Why it matters |
|---|---|
| 2.04M U.S. cancer cases | More demand for added services |
This is classic product development: more value per patient, same footprint, better retention.
Diversification
Turn clinical research into a separate revenue line
In 2025, The Oncology Institute can turn clinical research into a separate revenue line by opening more trial sites in new geographies and selling access to pharma-sponsored studies. Trial work brings a different mix of revenue than routine care because sponsors pay for protocol work, screening, and follow-up, not just visits. That makes the research network adjacent to oncology, but still a real step beyond standard clinic revenue.
For context, the global oncology drug market is above $200 billion, so sponsors have a large pool of trial demand to fund. If The Oncology Institute builds enough site density, research can add higher-margin revenue while deepening referral ties and patient access.
Offer oncology navigation to employers
In 2025, The Oncology Institute can sell oncology navigation to self-insured employers as a new service, not just a clinic visit, so it reaches a broader market than its current 5-state footprint. This fits employer demand for lower-cost site-of-care choices and tighter case management; self-insured plans cover about 63% of U.S. workers, so the channel is large. Packaging care coordination this way can scale without opening a new clinic in every market.
Provide practice management services externally
In fiscal 2025, The Oncology Institute can widen its moat by selling practice management services to independent oncologists in new regions. That MSO-style model adds a new revenue stream, so TOI earns fees for billing, staffing, payer work, and compliance without owning every clinic. It also scales low-capital know-how into a fragmented market, where small practices still need outside operating help.
Partner on specialty pharmacy support
Partnering on specialty pharmacy support lets The Oncology Institute expand into oral oncolytic support, adherence, and pharmacy coordination without adding exam-room volume. This is attractive because oral therapies now make up about 25% of oncology drug use, and specialty pharmacy spending in the US topped $300 billion in 2025, so the service line is both credible and commercially distinct.
- Fits the oncology ecosystem
- Reaches broader patient groups
Sell site-of-care analytics and contracting insight
Sell site-of-care analytics and contracting insight is a clear diversification move for The Oncology Institute: it sells a new service to a new buyer set, such as payers and health systems, in markets where The Oncology Institute does not yet run clinics. That can monetize oncology data, referral patterns, and care-pathway analytics without the capital burden of opening new sites, which is useful as oncology spending keeps rising and buyers look for lower-cost care settings.
The Oncology Institute Expands Beyond Clinics in 2025
In 2025, The Oncology Institute's diversification move is to sell oncology services beyond routine clinic visits, especially research, navigation, and payer analytics. These lines reach new buyers and markets, so revenue is less tied to one clinic footprint. That matters in a $200B-plus oncology drug market and a U.S. market where self-insured plans cover about 63% of workers.
| Move | 2025 signal |
|---|---|
| Research, navigation, analytics | New buyers, lower site dependence |
Frequently Asked Questions
The Oncology Institute drives penetration by concentrating volume inside its 100+ care sites, improving referral capture, and adding more services per episode. The most important levers are same-market density, payer alignment, and better retention across 5 states. In oncology, even modest gains in utilization can change economics quickly.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.